Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 5/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 0.72 |
| ▸ | DRD1 | P21728 | 2/20 | 0.72 |
| ▸ | DRD4 | P21917 | 2/20 | 0.72 |
| ▸ | DRD5 | P21918 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | HTR3B | O95264 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brilaroxazine SCHEMBL29368394 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL30999087 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL30900936 | 1.00 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL3405319 | 0.99 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Brilaroxazine SCHEMBL31038584 | 0.99 | DRD2 (0.98) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| SCHEMBL8160207 | 0.85 | DRD2 (0.80) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| SCHEMBL30964286 | 0.84 | DRD2 (0.84) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| SCHEMBL3408535 | 0.84 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| SCHEMBL31038574 | 0.84 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 | |
| Aripiprazole SCHEMBL982189 | 0.84 | DRD2 (1.00) | DRD2HTR1AHTR2AHTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071299-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | claimed |
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | REVIVA PHARMACEUTICALS, INC. | 2018-03-15 | — | — | US | claimed |
| EP-3244897-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | Reviva Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | claimed |
| EP-3244898-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | Reviva Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2016115150-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | REVIVA PHARMACEUTICALS INC. (US) | 2016-07-21 | — | — | WO | claimed |
| WO-2016115144-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | REVIVA PHARMACEUTICALS INC. (US) | 2016-07-21 | — | — | WO | claimed |
| US-12053477-B2 | Methods for treating pulmonary fibrosis | REVIVA PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-25 | — | — | US | disclosed |
| EP-3244896-B1 | METHODS FOR TREATING PULMONARY HYPERTENSION | REVIVA PHARMACEUTICALS INC (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118026945-A | Synthetic method of brimesalamine | 武汉工程大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-4340940-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | The Regents of University of California (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | REVIVA PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-8461154-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8431570-B2 | Methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | BHAT LAXMINARAYAN (US) | 2012-08-30 | — | — | US | disclosed |
| US-8188076-B2 | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188076-B2 | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071298-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, APP | DRD2 380/4885HTR1A 39/4885HTR2A 18/4885 |
| US-20120220579-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20180071299-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE | PARK7, SNCA, COMT | DRD2 87/4885HTR1A 27/4885HTR2A 33/4885 |
| US-20120220574-A1 | METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | HTR5A, GRIK5, HTR2A | DRD2 14/4885HTR1A 22/4885HTR2A 3/4885 |
| US-20230061592-A1 | METHODS FOR TREATING PULMONARY FIBROSIS | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-12053477-B2 | Methods for treating pulmonary fibrosis | MMP1, CCL11, PAH | DRD2 4417/4885HTR1A 1544/4885HTR2A 1984/4885 |
| US-20100216783-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | GRIK5, HTR5A, KYNU | DRD2 18/4885HTR1A 33/4885HTR2A 5/4885 |
| US-20240245693-A1 | COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY | ADORA2B, ADORA2A, ANXA3 | DRD2 2904/4885HTR1A 1170/4885HTR2A 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.